ArticleJAMA surgery2021
Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases.
Article in JAMA surgery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer.Cancer · 2022Pooled it
- Liver Transplantation for Non-Resectable Liver Metastases from Colorectal Cancer: A Systematic Review and Meta-Analysis.World journal of surgery · 2021Pooled it
- Optimal patient selection beyond the current selection criteria for liver transplantation for unresectable colorectal liver metastasis.Surgery today · 2026Review
- Liver transplantation as a new treatment option for perihilar cholangiocarcinoma and colorectal liver metastases: a review.International journal of clinical oncology · 2026Review
- Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation.Cancers · 2026Review
- Impact of portal vein embolisation uses in colorectal liver metastases: evidence from a rapid review.BMJ open · 2026Review
- Inclusion criteria for liver transplantation in patients with colorectal liver metastases: How to make the best selection?World journal of clinical oncology · 2025Review
- Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial.ESMO open · 2024Article
- Catheter-Directed Ionic Liquid Embolic Agent for Rapid Portal Vein Embolization, Segmentectomy, and Bile Duct Ablation.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Exploration of the Molecular Mechanism ofACS omega · 2024Article
- Liver Transplantation for Nonresectable Colorectal Liver Metastases (CRLM).Indian journal of surgical oncology · 2024Review
- Transplant oncology - Current indications and strategies to advance the field.JHEP reports : innovation in hepatology · 2024Review
- Molecular Mechanism ofDrug design, development and therapy · 2024Article
- Surgical approach to achieve R0 resections in primary and metastatic liver tumors: a literature review.Journal of gastrointestinal oncology · 2023Review
- Updates and Expert Opinions on Liver Transplantation for Gastrointestinal Malignancies.Medicina (Kaunas, Lithuania) · 2023Review
- ASO Author Reflections: Surgical Strategy for Bilobar Colorectal Liver Metastases with Vascular Invasion.Annals of surgical oncology · 2023Article
- New Insights in the Setting of Transplant Oncology.Medicina (Kaunas, Lithuania) · 2023Review
- Liver transplantation for unresectable colorectal liver metastases (CRLM) using extended criteria donor (ECD) grafts: proceed with caution.Hepatobiliary surgery and nutrition · 2023Article
- Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.Cancers · 2023Review
- Interventional radiological therapies in colorectal hepatic metastases.Frontiers in oncology · 2023Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Portal vein embolization (PVE) has been implemented in patients with extensive colorectal liver metastases to increase the number of patients able to undergo liver resection. Liver transplant could be an alternative in selected patients with extensive liver-only disease, and we have recently shown promising survival outcomes. Objective: To compare overall survival (OS) among patients with colorectal cancer and high liver metastasis tumor load who were treated with liver transplant or with PVE and liver resection. Design, Setting, and Participants: This comparative effectiveness research study assessed 50 patients with colorectal cancer liver metastases who were previously enrolled in liver transplant studies between November 2006 and August 2019 at Oslo University Hospital in Norway. Those patients were compared with a retrospective cohort of 53 patients in the Oslo University Hospital PVE database from March 2006 through November 2015 with similar selection criteria who underwent PVE and liver resection. Main Outcomes and Measures: The OS among patients with high tumor load after liver transplant was compared with that among patients with high tumor load who underwent PVE and liver resection. High tumor load was defined as 9 or more metastatic tumors or a diameter of 5.5 cm or longer for the largest liver lesion. Results: In the PVE cohort of 53 patients, the median age was 61.8 years (range, 34.3-71.3 years), and 36 patients (68%) were men. The 5-year OS rate among 38 patients who underwent liver resection after PVE was 44.6%. The 5-year OS rate for patients with high tumor load was 33.4% for those who underwent liver transplant and 6.7% for those who underwent PVE. Among patients with high tumor load and left-sided primary tumors, the 5-year OS rate was 45.3% for those receiving a liver allograft and 12.5% for those treated with PVE and liver resection. Conclusions and Relevance: Patients with nonresectable disease, an extensive liver tumor load, and left-sided primary tumors had long OS after liver transplant, exceeding the survival outcome for those patients treated with PVE and liver resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.